{"id":"W3049465296","doi":"10.1200/jco.20.00522","title":"Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Foundation Medicine; Genentech; U.S. Food and Drug Administration; Plexxikon; Sirtex Medical; Toray Industries; Springworks Therapeutics; Syndax Pharmaceuticals; BeiGene; Arog Pharmaceuticals; Agios Pharmaceuticals; Ipsen; Array BioPharma; Jazz Pharmaceuticals; Five Prime Therapeutics; Astex Pharmaceuticals; MacroGenics; Celldex Therapeutics; GlaxoSmithKline; IFM Therapeutics; American Society of Clinical Oncology; Valeant Pharmaceuticals International; Eli Lilly and Company; National Comprehensive Cancer Network; Iterion Therapeutics; Halozyme; Revolution Medicines; Karyopharm Therapeutics; Exelixis; Endocyte; Daiichi Sankyo Europe; National Cancer Institute; Calithera Biosciences; Gilead Sciences; Astellas Pharma; Eisai; FibroGen; Celgene; Bristol-Myers Squibb; Deciphera Pharmaceuticals; Amgen; Symphogen; Pfizer; PharmaMar; U.S. Department of Veterans Affairs","keywords":"Medicine; GiST; Internal medicine; Adverse effect; Nausea; Gastroenterology; Constipation; PDGFRA; Imatinib mesylate; Rash; Phases of clinical research; Oncology; Imatinib; Clinical trial; Stromal cell","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006180672,0.000656599,0.0008522227,0.0002783824,0.0001517376,0.0006140475,0.0003962685,0.0003999008,0.002700048],"category_scores_gemma":[0.0004126168,0.0002026833,0.0007540682,0.0002734574,0.0003101509,0.0004159206,0.0002110291,0.001715622,0.0004910073],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006898146,"about_ca_system_score_gemma":0.0006103238,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004545587,"about_ca_topic_score_gemma":0.001523524,"domain_scores_codex":[0.99978,0.00005722448,0.00001642405,0.00005313549,0.00004056372,0.00005273204],"domain_scores_gemma":[0.9998181,0.000027957,0.00005730186,0.00001703716,0.00001208467,0.00006753381],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2787372,0.04342873,0.01349683,0.002211277,0.002404724,0.0007601997,0.0004833962,0.004458122,0.1448492,0.0005201449,0.008808045,0.4998421],"study_design_scores_gemma":[0.4728009,0.4369794,0.04359398,0.0001205027,0.001748041,0.002591072,0.0001610462,0.003254198,0.02255954,0.0004467694,0.01567411,0.0000704381],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9914722,0.003668093,0.0004613062,0.0002362417,0.00006059116,0.0007983537,0.0004624413,0.0001144232,0.002726339],"genre_scores_gemma":[0.9942643,0.001424409,0.0007832857,0.0005396261,0.00005947903,0.0004980199,0.001100223,0.00001654489,0.001314051],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002700048,"threshold_uncertainty_score":0.009032607,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06473184962436974,"score_gpt":0.4269756399044538,"score_spread":0.3622437902800841,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}